Literature DB >> 7530854

Effects of diltiazem in convulsive states differ from those previously reported for dihydropyridine calcium channel antagonists.

W P Watson1, H J Little.   

Abstract

Unlike the dihydropyridine calcium channel antagonists studied previously, the benzothiazepine calcium channel antagonist, diltiazem, increased the incidence of convulsions caused by bicuculline, N-methyl-DL-aspartate or 4-aminopyridine. However, the latencies to convulsions were also increased. Diltiazem increased the ratings of convulsive behaviour on handling after intraperitoneal administration of bicuculline, or pentylenetetrazol and after the calcium channel activator, Bay K 8644, administered ICV. When the binding of the dihydropyridine, [3H]-nitrendipine in the CNS was measured in vivo, this was increased by diltiazem. This compound therefore showed a different pattern of interaction with convulsant drugs then that previously demonstrated for other calcium channel antagonists, appearing to possess both pro- and anticonvulsant actions, and a different pattern of interaction with the dihydropyridine receptor complex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530854     DOI: 10.1007/bf02244855

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  30 in total

1.  A new class of calcium entry blockers defined by 1,3-diphosphonates. Interactions of SR-7037 (belfosdil) with receptors for calcium channel ligands.

Authors:  J R Rossier; J A Cox; E J Niesor; C L Bentzen
Journal:  J Biol Chem       Date:  1989-10-05       Impact factor: 5.157

2.  Anticonvulsant effects of some calcium entry blockers in DBA/2 mice.

Authors:  G B De Sarro; B S Meldrum; G Nisticó
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

3.  Influence of calcium channel inhibitors upon the anticonvulsant efficacy of common antiepileptics against pentylenetetrazol-induced convulsions in mice.

Authors:  S J Czuczwar; U Małek; Z Kleinrok
Journal:  Neuropharmacology       Date:  1990-10       Impact factor: 5.250

4.  Effects of Ca++ on [3H]diltiazem binding and its allosteric interaction with dihydropyridine calcium channel binding sites in the rat cortex.

Authors:  H Schoemaker; S Z Langer
Journal:  J Pharmacol Exp Ther       Date:  1989-02       Impact factor: 4.030

5.  Suppression of pentylenetetrazole seizures by oral administration of a dihydropyridine Ca2+ antagonist.

Authors:  F B Meyer; R E Anderson; T M Sundt; T L Yaksh; F W Sharbrough
Journal:  Epilepsia       Date:  1987 Jul-Aug       Impact factor: 5.864

6.  Effects of diltiazem on hyperthermia induced seizures in the rat pup.

Authors:  M L Laorden; E Carrillo; F S Miralles; M M Puig
Journal:  Gen Pharmacol       Date:  1990

7.  The interaction of [3H]PY 108-068 and of [3H]PN 200-110 with calcium channel binding sites in rat brain.

Authors:  P Supavilai; M Karobath
Journal:  J Neural Transm       Date:  1984       Impact factor: 3.575

8.  Dihydropyridine binding sites regulate calcium influx through specific voltage-sensitive calcium channels in cerebellar granule cells.

Authors:  E Carboni; W J Wojcik
Journal:  J Neurochem       Date:  1988-04       Impact factor: 5.372

9.  "Calcium entry blockers" as cerebral protecting agents: comparative activity in tests of hypoxia and hyperexcitability.

Authors:  A Wauquier; D Ashton; G Clincke; J Fransen
Journal:  Jpn J Pharmacol       Date:  1985-05

10.  Bay K 8644 induces a reversible spasticity-like syndrome in rats.

Authors:  E N Petersen
Journal:  Eur J Pharmacol       Date:  1986-11-04       Impact factor: 4.432

View more
  2 in total

1.  Interactions between diltiazem and ethanol: differences from those seen with dihydropyridine calcium channel antagonists.

Authors:  W P Watson; H J Little
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

2.  The differential effects of felodipine and nitrendipine on cerebral dihydropyridine binding ex vivo and the ethanol withdrawal syndrome in mice.

Authors:  W P Watson; A Misra; A J Cross; A R Green; H J Little
Journal:  Br J Pharmacol       Date:  1994-08       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.